Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Prandin (Repaglinide) – US: Supreme Court sides with generic pharmaceutical companies in dispute over Orange Book “use codes”: Caraco v Novo Nordisk (Orange Book Blog) (FDA Law Blog) (Patently-O)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Top 5 countries by percent of pharmaceutical applications (Patent Quality Matters)

Medicines Patent Pool Director Ellen ‘t Hoen to leave next month (IP Watch)

Views on the Report of the WHO Consultative Expert Working Group on Research and Development (CEWG) (KEI)

Can the combination of creative destruction and “Steve Jobs’ traits” lead to pharma QbD Spring? (profitability through simplicity)

Belgium: Does Belgian patent law need a breeders exemption? (EPLAW)

EU: Analysis of SPCs affected by Medeva (The SPC Blog)

US: En banc CAFC requires reexam claim amendments for intervening rights: Marine Polymer Technologies v Hemcon (Pharma Patents) (Patent Docs)

US: CAFC affirms motion to compel arbitration in patent licensing dispute: Promega v Life Technologies (Patent Docs)

US: Patenting health: You cannot own the laws of nature: Mayo v Prometheus (IP Osgoode)

US: Exergen, not Therasense, governs pleading standard for inequitable conduct: Bayer CropScience v Dow Agrosciences (Docket Report)

US: District Court Maryland: The missing inventor: Stemcells v Neuralstem (Property, intangible)

US: Veterinary drug compounding: Franck’s Lab takes FDA to task in the 11th Circuit; picks off each of the government’s arguments (FDA Law Blog)

US: Precision BioSciences files two suits against Cellectis alleging infringement of patents relating to methods of cleaving DNA (Patent Docs)

 

Products

Cubicin (Daptomycin) – US: Cubist files patent infringement complaint against Hospira in response to Para IV challenge (Patent Docs)

Duexis (Famotidine and Ibruprofen) – US: Horizon files patent infringement complaint against Par Pharmaceuticals in response to Para IV certification filing (Patent Docs)

Exelon (Rivastigmine) – France: Paris appeal court grants preliminary injunction and orders recall of Mylan and Qualimed’s generic products: Novartis v Mylan and Qualimed (EPLAW)

Exjade (Deferasirox) – US: Novartis files patent infringement suits against Actavis companies in Delaware and New Jersey in response to Para IV challenge (Patent Docs)

Lumigan (Bimatoprost) – US: Allergan files patent infringement suit against Watson in response to Para IV certification filing (Patent Docs)

Prandin (Repaglinide) – US: Supreme Court sides with generic pharmaceutical companies in dispute over Orange Book “use codes”: Caraco v Novo Nordisk (Orange Book Blog) (FDA Law Blog) (Patently-O)

Taxotere (Docetaxel) – US: CAFC finds inequitable conduct for the first time since Therasense: Aventis v Hospira (Maier & Maier) (Orange Book Blog)

Vancocin (Vancomycin) – US: ViroPharma sues FDA – challenges denial of 3-year exclusivity and ANDA approvals (FDA Law Blog)

Viagra (Sildenifil) – Canada: Disclosure front and centre as Pfizer prepares to defend Viagra in Supreme Court of Canada (IP Osgoode)

Xopenex (Levosalbutamol) – US: CAFC finds subject-matter jurisdiction and affirms dictrict court judgment of non-infringement: Dey Pharma v Sunovion (Patent Docs)